• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Not So Different: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market

Podcast

We spoke to Charles Bennett, MD, PhD, a clinical pharmacy specialist, about his recent oncology biosimilars study and how pay-for-delay schemes have somewhat stalled the biosimilar market.

Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, served as lead author on a recent paper about the progress of oncology biosimilars. We spoke to him about the some of the findings of his study and how pay-for-delay schemes have somewhat stalled the biosimilar market.

To read more about Bennett's study, click here.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Travis Brewer, Texas Oncology
Tiago Biachi, MD, PhD
GBW 2023 webinar
© 2025 MJH Life Sciences

All rights reserved.